Dynavax Technologies Corporation (DVAX)

NASDAQ: DVAX · IEX Real-Time Price · USD
13.01
+0.02 (0.15%)
Feb 28, 2024, 3:18 PM EST - Market open
0.15%
Market Cap 1.72B
Revenue (ttm) 232.28M
Net Income (ttm) -6.39M
Shares Out 130.62M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 47.90
Dividend n/a
Ex-Dividend Date n/a
Volume 659,986
Open 12.89
Previous Close 12.99
Day's Range 12.85 - 13.09
52-Week Range 9.42 - 15.15
Beta 1.26
Analysts Buy
Price Target 25.00 (+92.16%)
Earnings Date Feb 22, 2024

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In... [Read more]

Sector Healthcare
IPO Date Feb 19, 2004
Employees 408
Stock Exchange NASDAQ
Ticker Symbol DVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $25.0, which is an increase of 92.16% from the latest price.

Price Target
$25.0
(92.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dynavax to Present at TD Cowen's 44th Annual Health Care Conference

EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

20 hours ago - PRNewsWire

Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

HEPLISAV-B ® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expecte...

5 days ago - PRNewsWire

Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024

EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will...

19 days ago - PRNewsWire

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Preliminary full year 2023 HEPLISAV-B ® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments, wi...

7 weeks ago - PRNewsWire

Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...

7 weeks ago - PRNewsWire

20 favorite small-cap stocks for 2024 among Wall Street analysts

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...

2 months ago - Market Watch

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

3 months ago - PRNewsWire

Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

Generated quarterly HEPLISAV-B ® vaccine net product revenue of $62.3 million, a 66% year-over-year increase Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared ...

4 months ago - PRNewsWire

Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...

4 months ago - PRNewsWire

Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference

EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...

4 months ago - PRNewsWire

Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

6 months ago - PRNewsWire

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

Generated record quarterly HEPLISAV-B ® vaccine net product revenue of $56 million, a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compa...

7 months ago - PRNewsWire

Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...

7 months ago - PRNewsWire

Dynavax to Present at Upcoming Investor Conferences

EMERYVILLE, Calif. , May 30, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...

9 months ago - PRNewsWire

Dynavax to Present at the JMP Securities Life Sciences Conference

EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today...

10 months ago - PRNewsWire

Dynavax Reports First Quarter 2023 Financial Results

HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $...

10 months ago - PRNewsWire

Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023

EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...

11 months ago - PRNewsWire

Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an updat...

Other symbols: VALN
1 year ago - GlobeNewsWire

Dynavax to Present at the Cowen 43rd Annual Health Care Conference

EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

1 year ago - PRNewsWire

Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine

HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a bi...

1 year ago - PRNewsWire

Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance

2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B ®  vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018® adjuvant vaccine net...

1 year ago - PRNewsWire

Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will...

1 year ago - PRNewsWire

Dynavax Announces Uplisting to the Nasdaq Global Select Market

EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation  (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative v...

1 year ago - PRNewsWire

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, br...

1 year ago - GlobeNewsWire

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results

Preliminary full year 2022 HEPLISAV-B® vaccine Net Product Revenue of approximately $126 million, representing 104% growth compared to 2021 Preliminary full year CpG 1018® adjuvant Net Product Revenue...

1 year ago - PRNewsWire